Scientists have deciphered the molecular architecture of the nanomachines that are secreted during Mycobacterium tuberculosis infection.
The molecular architecture of the nanomachines that are secreted during Mycobacterium tuberculosis infection has been deciphered by scientists from the Julius-Maximilians-Universität Würzburg (JMU) and the Spanish Cancer Research Centre CNIO (Centro Nacional de Investigaciones Oncológicas). Tuberculosis is a highly contagious infectious disease that is typically spread through aerosols and mainly affects the lungs. In addition, a quarter of the world's population carries a form of tuberculosis that lies dormant without symptoms for a long time, but can break out eventually.
‘According to the World Health Organization (WHO), an estimated 1.7 million people die from such an infection worldwide every year.’
Nanomachines in the cell envelope During infection Mycobacterium tuberculosis, the main causative agent of tuberculosis, secretes a large number of effector proteins through type VII secretion systems - small nanomachines which are composed of proteins that reside in the cell envelope. The effector proteins are specialized in fighting the immune defense or enable the uptake of nutrients to ensure the bacterial survival in the host. How these central secretion systems work, is still poorly understood.
Dr. Sebastian Geibel, who heads a research group at the Institute of Molecular Infection Biology funded by the Bavarian Elite Network and who is also affiliated with the Rudolf Virchow Centre of the JMU, was in charge of this work. The scientists have published their work in the current issue of the journal Nature.
Measurements at very low temperatures
Over the past five years, the research group of Dr. Geibel has worked intensively on the stable reconstitution of one of these secretion machines and the preparation of the sensitive sample for measurements on the cryo electron microscope, which requires the protein complexes to be shock frozen under defined conditions.
Advertisement
New approach for new drugs
Advertisement
Source-Eurekalert